These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 4648587)

  • 1. [Behavior of uremic hyperlipemia and disturbances of glucose tolerance under chronic intermittent hemodialysis treatment].
    Hübner W; Diemer A; Freiberg J
    Med Welt; 1972 Oct; 23(41):1415-7. PubMed ID: 4648587
    [No Abstract]   [Full Text] [Related]  

  • 2. Glucose, insulin and glucagon response to intravenous glucose load in patients on chronic hemodialysis.
    Shasha SM; Nusem D; Kanter Y; Weiner F
    Isr J Med Sci; 1988 Jan; 24(1):15-9. PubMed ID: 3279011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronary risk in patients with endstage renal disease: interaction of hypertension with hyperlipidemia.
    Goldberg AP; Tindira C; Harter HR
    J Cardiovasc Pharmacol; 1982; 4 Suppl 2():S257-61. PubMed ID: 6177969
    [No Abstract]   [Full Text] [Related]  

  • 5. [Aspects of carbohydrate metabolism in chronic uremic patients treated with periodic hemodialysis: determination of phosphoremia during some dynamic tests].
    Redaelli B; Salvadeo A; Imbasciati E; Ponticelli C
    Arch Ital Urol Nefrol; 1967; 39(6):459-67. PubMed ID: 5606789
    [No Abstract]   [Full Text] [Related]  

  • 6. [Aspects of carbohydrate metabolism in chronic uremic patients treated with periodic hemodialysis].
    Redaelli B; Salvadeo A; Ponticelli C; Imbasciati E; Graziani G
    Minerva Nefrol; 1967; 14(4):158-62. PubMed ID: 5607555
    [No Abstract]   [Full Text] [Related]  

  • 7. [Mortality in patients with chronic renal insufficiency undergoing hemodialysis. Hyperlipemia as coadjuvant factor].
    Joven J; Vilella E; Brunzell JD
    Med Clin (Barc); 1991 Jan; 96(3):110-3. PubMed ID: 2033971
    [No Abstract]   [Full Text] [Related]  

  • 8. The determination of insulin sensitivity in hemodialysis and continuous ambulatory peritoneal dialysis in nondiabetic patients with end-stage renal disease.
    Tuzcu A; Bahceci M; Yilmaz ME; Turgut C; Kara IH
    Saudi Med J; 2005 May; 26(5):786-91. PubMed ID: 15951871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disorders of carbohydrate and lipid metabolism in uremia.
    Bagdade
    Nephron; 1975; 14(2):153-62. PubMed ID: 1093054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The visual apparatus in chronic uremic patients during periodic hemodialytic treatment. 3. Changes in the caliber of the retinal vessels during hemodialysis].
    Sorice PS; Esposito E; Tretola L; Tufano L; Ambrosio A
    Rass Int Clin Ter; 1971 Aug; 51(15):948-52. PubMed ID: 5096694
    [No Abstract]   [Full Text] [Related]  

  • 11. [Behavior of plasma glucose and glucose uptake in the organism during extracorporal hemodialysis].
    Schultis K; Schmidt HG
    Med Welt; 1971 Jan; 3():89-95. PubMed ID: 5545601
    [No Abstract]   [Full Text] [Related]  

  • 12. Are biocompatible membranes superior for hemodialysis therapy?
    van Ypersele de Strihou C
    Kidney Int Suppl; 1997 Nov; 62():S101-4. PubMed ID: 9350694
    [No Abstract]   [Full Text] [Related]  

  • 13. Uremic lipemia: an unrecognized abnormality in triglyceride synthesis and removal.
    Bagdade JD; Porte D; Curtis FK; Bierman EL
    Trans Assoc Am Physicians; 1968; 81():190-202. PubMed ID: 5721400
    [No Abstract]   [Full Text] [Related]  

  • 14. Residual function in chronic renal insufficiency under regular dialysis treatment.
    Erben J
    Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove; 1980; 23(1):1-112. PubMed ID: 6966816
    [No Abstract]   [Full Text] [Related]  

  • 15. [Relationship between uremia polyneuropathy, uremic glucose metabolism disorder and severity of uremic intoxication in dialysis patients].
    Goubeaud G; Kunze K; Hohmann KH; Schütterle G; Biro G
    Verh Dtsch Ges Inn Med; 1974; 80():728-31. PubMed ID: 4454650
    [No Abstract]   [Full Text] [Related]  

  • 16. [Immunological parameters in uremic patients under hemodialysis].
    Pigareva NV; Polenova IM
    Klin Med (Mosk); 1981 Mar; 59(3):75-9. PubMed ID: 7265837
    [No Abstract]   [Full Text] [Related]  

  • 17. [Hyperkaliemic complication in patients undergoing periodical hemodialysis].
    Perna N; De Pascale C; Cirillo D; Giordano C
    Minerva Nefrol; 1970; 17(3):83-4. PubMed ID: 5515030
    [No Abstract]   [Full Text] [Related]  

  • 18. [Intermittent hemodialysis in terminal chronic nephropathy in Fredericia Hospital].
    Birkeland SA; Hoffmeyer J; Rojel J
    Ugeskr Laeger; 1969 Mar; 131(12):511-9. PubMed ID: 5793607
    [No Abstract]   [Full Text] [Related]  

  • 19. [Hemosorption as a treatment method for uremic complications].
    Pilotovich VS; Ostapenko VA; Shilaĭ LM; Kirkovskiĭ VV; Nikolaĭchik VV
    Klin Med (Mosk); 1982 Apr; 60(4):77-80. PubMed ID: 7098397
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effect of hemodialysis on the course of blood sugar curve in patients with chronic renal failure].
    Poplawski A; Oleńska T
    Pol Tyg Lek; 1974 Oct; 29(42):1781-3. PubMed ID: 4419200
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.